LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material Norethindrone Tablets USP

0.35 mg

Manufacturer Lupin Limited

Pithampur (M.P.) – 454 775

INDIA

Distributor Lupin Pharmaceuticals, Inc.

111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202

United States

Tel. 001-410-576-2000 Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion Expected to be non-combustible.

Health Progestin-only oral contraceptives (POPs) should not be used by women

who currently have the following conditions:

Known or suspected pregnancy

Known or suspected carcinoma of the breast

Undiagnosed abnormal genital bleeding

Hypersensitivity to any component of this product

Benign or malignant liver tumors

Acute liver disease

Environment No information is available about the potential of this product to produce

adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

Ingredients CAS

Norethindrone USP 68-22-4

Section 4: First-Aid Measures

Section 4, First-aid measures

Immediately give large quantities of water to drink. Never give anything by

mouth to a victim who is unconscious or is having convulsions.

Call a physician immediately.

SDS : 057/02 Page 1 of 4

Inhalation Remove to fresh air. If breathing stops, provide artificial respiration.

Get medical attention immediately.

Skin Contact Wash off immediately with plenty of water. Continue to rinse for at least

15 minutes. Immediately take off all contaminated clothing.

Get medical attention if irritation develops and persists.

Eye Contact Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment Treat according to locally accepted protocols. For additional guidance,

refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the

patient's vital signs, blood gases, serum electrolytes, etc.

OVERDOSAGEThere have been no reports of serious ill effects from overdosage,

including ingestion by children.

Section 5: Fire-Fighting Measures

Section 5, Fire-fighting measures

Fire and Explosion Hazards Assume that this product is capable of sustaining combustion.

Extinguishing Media Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures For single units (packages): No special requirements needed.

For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus

and full protective equipment are recommended for firefighters.

Hazardous Combustion Products Hazardous combustion or decomposition products are expected when the

product is exposed to fire.

Section 6: Accidental Release Measures

Section 6, Accidental release measures

Personal PrecautionsWear suitable protective clothing, gloves and eye/face protection.

Environmental PrecautionsAvoid release to the environment.

Clean-up Methods Collect and place it in a suitable, properly labeled container for recovery or

disposal.

Section 7: Handling and Storage

Section 7, Handling and storage

Handling No special control measures required for the normal handling of this

product.

Normal room ventilation is expected to be adequate for routine handling of

this product.

SDS : 057/02 Page 2 of 4

Storage

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]

Section 8: Exposure Controls/Personal Protection

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form

Norethindrone Tablets USP containing 0.35 mg of norethindrone, are yellow coloured, round flat face beveled edge tablets debossed with "LU" on one side and "J22" on the other side.

Norethindrone Tablets USP are available in a blister (NDC 68180-876-71) containing 28 tablets. Three such blisters are packaged in a carton (NDC 68180-876-73).

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

The product is stable and non-reactive under normal conditions of use, storage and transport.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Some epidemiologic studies of oral contraceptive users have reported an increased relative risk of developing breast cancer, particularly at a younger age and apparently related to duration of use. These studies have predominantly involved combined oral contraceptives and there is insufficient data to determine whether the use of POPs similarly increase the risk. Women with breast cancer should not use oral contraceptives because the role of female hormone in breast cancer has not been fully determined.

Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. There is insufficient data to determine whether the use of POPs increases the risk of developing cervical intraepithelial neoplasia.

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

SDS : 057/02 Page 3 of 4

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated

IMDG Proper shipping Name:N/AIMDG UN/ID No:N/AIMDG Hazard Class:N/AIMDG Flash Point:N/AIMDG Label:N/A

DOT - Not Regulated

DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.

SDS : 057/02 Page 4 of 4